Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
Domenico Viola, Ada Donà, Enrico Caserta, Estelle Troadec, Francesca Besi, Tinisha McDonald, Lucy Ghoda, Emine Gulsen Gunes, James F. Sanchez, Jihane Khalife, Marianna Martella, Chatchada Karanes, Myo Htut, Xiuli Wang, Michael Rosenzweig, Arnab Chowdhury, Douglas W. Sborov, Rodney R. Miles, Paul J. Yazaki, Todd Ebner, Craig C. Hofmeister, Stephen J. Forman, Steven T. Rosen, Guido Marcucci, John E. Shively, Jonathan J. Keats, Amrita Krishnan, Flavia Pichiorri
Topics & Concepts
DaratumumabCD38Immune systemImmunologyCD86BiologyCD80Interleukin 21Cancer researchT cellCell biologyCytotoxic T cellAntibodyCD40Stem cellIn vitroMonoclonal antibodyCD34BiochemistryMultiple Myeloma Research and TreatmentsImmune Cell Function and InteractionT-cell and B-cell Immunology